Hokusai VTE-Cancer Study: Edoxaban vs Dalteparin for VTE in Adult Cancer Patients

December 9-12, 2017; Atlanta, Georgia
Oral edoxaban was noninferior to subcutaneous dalteparin regarding combined risk of recurrent VTE or major bleeding in patients with cancer-associated VTE.
Format: Microsoft PowerPoint (.ppt)
File Size: 246 KB
Released: December 14, 2017


This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation

Related Content

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2022, from Clinical Care Options (CCO)

David Scott Miller, MD, FACOG, FACS Angeles Alvarez Secord, MD, MHSc Released: June 22, 2022

Downloadable slideset from a local live webinar developed by lymphoma experts with guidance on the management of indolent lymphomas

Elizabeth Brém, MD Christopher R. Flowers, MD, MS Released: June 21, 2022

Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 20, 2022

Phase III MITO23: data on trabectedin vs investigator’s choice of chemotherapy in BRCA-mutant or BRCAness phenotype recurrent ovarian cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings